Digital health in Q3 2025 is a split screen.
On one side, a handful of companies are raising massive rounds, signaling investor confidence and a supposed market rebound. On the other, hundreds of startups are waiting longer, raising less, and facing harder questions about their survival.
Both Rock Health (U.S.) and Galen Growth (Global) capture this contrast vividly. Their latest Q3 reports paint a shared picture of a market consolidating around quality, but differ on just how deep the divide runs.
Let’s unpack what they agree on, where they differ, and what it all means for digital health heading into 2026.
Inside Rock Health’s Q3 2025 report
Rock Health’s latest numbers show an industry that looks healthy on the surface, until you dig deeper.
The concentrated flow of capital
- Total Q3 2025 funding: $3.5 billion raised across 107 deals in Q3 2025, bringing year-to-date (YTD) funding to $9.9 billion, already ahead of 2024’s pace ($8.4 bn).
- Capital concentration in mega-deals: This growth is heavily concentrated by 19 mega-deals of over $100 Mn, making up 39% of all funding.
- Inflated average deal size: The capital concentration has driven the YTD 2025 average deal size to $28.1 million, an increase from the $20.4 million average in 2024.
What’s happening: The thinning middle and protracted timelines
The funding middle has vanished. Beyond the headline-grabbing mega-deals, the early- and mid-stage startups are caught in a difficult and protracted funding drought.
- Series B bottleneck: Series B rounds have nearly halved, with only 30 completed so far in 2025 (historically 60+).
- Prolonged timelines: The median gap between Series A and B has stretched to 27 months, up from 17 months in 2023.
As a result, only the strongest companies with scale, traction, or clear workflows are advancing.
Strategic focus: Workflow is the king
Rock Health calls it the “workflow ownership contest.” Nearly 42% of all funding is flowing into workflow solutions, both clinical and administrative. Investors are betting on platforms that can sit at the core of healthcare delivery.
Meanwhile, M&A activity is surging, with 166 acquisitions through Q3, already 37% above 2024’s full-year total. Most involve startups buying each other to expand their product stack and own more of the workflow chain.
The most popular acquisitions are EHR and workflow assets, which make up 16% of the total deals.
Galen Growth’s Q3 2025 healthtech outlook
Galen Growth, which tracks global healthtech trends, offers a wider lens. Its Q3 report describes a transitional quarter, marked by investor selectivity, AI dominance, and consolidation around proven ventures.
Q3 2025 funding overview
The Q3 2025 digital health market demonstrated a clear shift towards quality.
- Total funding: $5.7 billion raised across 234 deals in Q3 (down 23% from Q2).
- YTD total: $20.6 billion across 964 deals (down 4% YoY).
- Average deal size: up to $28.8 million, showing a “quality over quantity” focus.
- Strong finish: Investor interest surged in September, with a 74% monthly increase in activity and 294 active investors.
- Annual forecast: Full-year 2025 global funding is projected to reach $25–26 billion.
What’s driving investment
AI is the new backbone: The market has shifted from”AI-as-hype” to “AI-with-evidence,” with major funding flowing to ventures with proven clinical or operational ROI.
- Big rounds include EliseAI ($250M) and Ambience Healthcare ($243M).
- There have already been 38 global mega-deals worth over $100M in 2025.
Intense capital concentration: A “quality over quantity” narrative dominated, with the top 10 funding rounds alone accounting for 35% of Q3’s total capital. Key deals include Strive Health ($300M Series D), Judi Health ($252M Series F), and Oura ($250M Debt Financing).
Partnerships and exits: While partnerships have dropped 52% year-on-year, exits remain strong with 165 venture exits YTD, many driven by strategic buyers from pharma and medtech.
Therapeutic hotspots: Funding is heavily concentrated in high-impact therapeutic areas: Oncology ($3.1B), Women’s Health ($2.5B), and Mental Health ($2.1B).
Galen Growth’s narrative is less about contraction and more about refinement. Capital is consolidating into ventures that have clear evidence, traction, and scalable models.
Comparing Galen Growth and Rock Health on Digital Health in Q3 2025 State
The reports from Rock Health and Galen Growth on Digital Health in Q3 2025 offer a consistent macro narrative but diverge significantly on the scope and magnitude of funding.
Where they agree:
Both reports confirm a fundamental market shift centered on:
- Flight to quality: Both see capital clustering around a few proven, late-stage ventures with mega deals and inflating average deal size.
- Strategic focus on core infrastructure: Investment is clustering around the healthcare “operating layer,” whether that’s AI engines (Galen Growth) or workflow platforms (Rock Health).
- Robust M&A activity: Mergers and acquisitions are the dominant exit strategy, signaling a market ripe for consolidation.
- The demand for evidence: The era of hype is over; ventures must now demonstrate proven clinical or operational value to secure significant funding.
Where they differ:
Key differences arise from geographic focus and resulting perspectives:
- Funding scale: Galen Growth’s global YTD total of $20.6B is more than double Rock Health’s US-only total of $9.9B, highlighting the substantial contribution of international markets.
- Market outlook: Rock Health warns of a widening divide, a “thinning middle” and a severe Series B bottleneck. A market top-heavy with capital but weak in mid-tier resilience. Galen Growth, meanwhile, frames 2025 as a recalibration year. A necessary step toward maturity.
- Investment lens: Rock Health looks at how healthcare is delivered (workflow ownership), while Galen Growth focuses on what is being delivered (therapeutic and AI-led innovations).
What it all means
Both reports tell the same underlying truth: digital health is consolidating, not collapsing.
Capital hasn’t disappeared. It’s just gotten pickier. The days of funding on vision alone are over. Investors now want proof: real-world results, validated AI models, and sustainable economics.
For startups, this means the path to funding is longer, but the bar for success is clearer. For investors, it’s a market of fewer, stronger bets on companies that are becoming the infrastructure of healthcare’s digital future.
As we close Q3 2025, digital health stands at a crossroads. The winners will be those who can prove both clinical value and operational endurance. The rest will have to adapt fast or risk being left behind in the next wave of consolidation.
Wrapping up
The Rock Health and Galen Growth reports don’t contradict each other; rather, they complement each other. One looks inward at the U.S. system under strain; the other outward at a global market recalibrating toward maturity.
Together, they reveal an industry in transition.
-By Alkama Sohail and the AHT Team
